Isuzinaxib
Phase 2In a Korean Phase 2b for diabetic kidney disease; dosing in its global Phase 2 for contrast-induced acute kidney injury finished in April 2026.
FROM PUBLIC EVENTS · 2026-11-18
Early clinical · first deals Running kidney-disease Phase 2 trials alongside Phase 1 programmes in oncology and ophthalmology.
Roles often seen at this stageClinical & PV · Regulatory affairs · Research & development
A drug developer using NOX-inhibitor/CAF-modulation and Apta-DC platforms for kidney disease, oncology and ophthalmology.
In a Korean Phase 2b for diabetic kidney disease; dosing in its global Phase 2 for contrast-induced acute kidney injury finished in April 2026.
An immuno-oncology candidate whose first human Phase 1 data from Korea were presented at ASCO 2026.
An oral candidate for age-related macular degeneration; US FDA cleared its Phase 1 IND in October 2025.
Completed dosing in the global Phase 2 of isuzinaxib for contrast-induced acute kidney injury.
Presented first Phase 1 data for APX-343A at ASCO 2026.
Received US FDA clearance of the Phase 1 IND for ABF-101.
Official role guide
Observed 2026-11-18
Information from a role guide does not establish a current vacancy.
A brief based on selected official material, not an exhaustive product or vacancy list.